Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 2CNS 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Neuroendocrine Tumors 1Disease 1Carcinoid Tumor 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 7Magnetic Resonance Spectroscopy 7pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Nivolumab 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Lutetium-177 2Ipilimumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Ga(III)-DOTATOC × NET × Clear all
NCT07150546 2026-03-02

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Emory University

Phase 1 Recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Stanford University

Phase 1 Recruiting
10 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT02359500 2017-05-03

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Icahn School of Medicine at Mount Sinai

Phase 1 Terminated
71 enrolled
EndocrineNET

Carcinoid Tumor, Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡